The European Commission Approves AstraZeneca's Tagrisso (Osimertinib) With Pemetrexed And Platinum-Based Chemotherapy As 1st-line Treatment For Advanced EGFR-Mutated Non-small Cell Lung Cancer Whose Tumors Have Exon 19 Deletions Or Exon 21 Mutations
The European Commission Approves AstraZeneca's Tagrisso (Osimertinib) With Pemetrexed And Platinum-Based Chemotherapy As 1st-line Treatment For Advanced EGFR-Mutated Non-small Cell Lung Cancer Whose Tumors Have Exon 19 Deletions Or Exon 21 Mutations
歐洲委員會批准阿斯利康（AstraZeneca）的Tagrisso（奧西替尼）與培美曲塞和鉑金類化療聯用作爲EGFR突變的非小細胞肺癌的一線治療，該腫瘤的外顯子19缺失或外顯子21突變。
The European Commission Approves AstraZeneca's Tagrisso (Osimertinib) With Pemetrexed And Platinum-Based Chemotherapy As 1st-line Treatment For Advanced EGFR-Mutated Non-small Cell Lung Cancer Whose Tumors Have Exon 19 Deletions Or Exon 21 Mutations
歐洲委員會批准阿斯利康（AstraZeneca）的Tagrisso（奧西替尼）與培美曲塞和鉑金類化療聯用作爲EGFR突變的非小細胞肺癌的一線治療，該腫瘤的外顯子19缺失或外顯子21突變。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。